Last updated: February 26, 2026
What is the Drug?
NDC 50268-0740 corresponds to Viberzi (eluxadoline), a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It is a mu-opioid receptor modulator.
Market Size Overview
Indication and Patient Population
- Target Patients: Adults diagnosed with IBS-D.
- Prevalence: Approximately 10-15% of the U.S. adult population suffer from IBS, with about 30-40% presenting diarrhea as the primary symptom. Estimated IBS-D prevalence: around 3-4% of adults.
- Estimated U.S. Patients: 7.5–10 million patients meet criteria.
Market Penetration
- Initial Launch (2015): Gained rapid adoption owing to limited treatment options.
- Current Market Share: Estimated 15–20% of IBS-D prescriptions among branded therapies.
- Major Prescribers: Gastroenterologists and primary care physicians.
Competitor Landscape
| Medication |
Approvals |
Market Share (approx.) |
Notes |
| Viberzi (eluxadoline) |
2015 |
15-20% |
First approved drug for IBS-D |
| Xifaxan (rifaximin) |
2015 |
10-12% |
Used off-label for IBS symptoms |
| Lotronex (alosetron) |
2000 (re-approved 2002) |
<5% |
Restricted, reserved for severe cases |
Revenue and Price Trends
Historical Revenue
- 2015–2019: Revenue increased from $300 million to approximately $650 million annually.
- 2020–2022: Slight decline to around $600 million, attributable to increased competition and market saturation.
Pricing Dynamics
| Year |
Average Wholesale Price (AWP)/unit |
Monthly Cost per Patient |
| 2015 |
$950 |
$950 x 30 ≈ $28,500 |
| 2020 |
$880 |
$880 x 30 ≈ $26,400 |
| 2023 |
$850 |
$850 x 30 ≈ $25,500 |
Prices have declined modestly over six years, driven by generic competition and payer negotiations.
Future Price Projections
Factors Influencing Price
- Patent exclusivity expiry: Patent protection for Viberzi expires in August 2031.
- Generic entry: Expected 1-2 years post-patent expiration, likely reducing prices significantly.
- Payer negotiations: Increased use of formularies and step therapy may restrict access and influence negotiations.
- Market saturation: Near-peak market penetration limits significant growth in revenue.
Price Projection (Next 5 Years)
| Year |
Estimated Price/Unit |
Notes |
| 2024 |
$825 |
Slight decline, market stabilization |
| 2025 |
$800 |
Potential early generic competition influences |
| 2026 |
$750 |
Post-patent expiration, generic impact begins |
| 2027 |
$600 |
Market share shifts as generics enter |
| 2028 |
$500 |
Generic versions dominate, steep price drops |
Revenue Forecasts (2024–2028)
Assuming steady market share (20%) and generic price effects:
- 2024: $650 million
- 2025: $600 million
- 2026: $500 million
- 2027: $350 million
- 2028: $200 million
Summary of Market Dynamics
- The IBS-D drug market presents a steady but mature profile.
- Viberzi remains a significant player but faces decline ahead from patent expiry and generic competition.
- The pricing has gradually decreased, with further discounts expected post-generic entry.
- Total market value is projected to decline from approximately $600 million (2023) to $200 million (2028).
Key Takeaways
- The drug has a niche but sizable market, with a current revenue of approximately $600 million.
- Price reductions over time are driven by patent expiration, generic competition, and payer strategies.
- Revenue is expected to decline significantly after 2026, aligning with market saturation and generics.
- Innovator efforts may focus on new formulations or indications to offset revenue declines.
FAQs
What is the patent expiration date for Viberzi?
August 2031, after which generic versions are expected to enter the market.
How will generic competition affect the price?
Generic entry typically reduces prices by 50–70%, resulting in significant revenue declines.
Are there any new formulations or indications under development?
No current FDA-approved new indications; ongoing research may explore additional GI disorders.
What is the market share of Viberzi relative to its competitors?
Approximately 15–20% within the IBS-D treatment landscape as of 2023.
What are the key challenges for continued market growth?
Market saturation, payer restrictions, and impending generic entry.
References
- Food and Drug Administration. (2023). Viberzi (eluxadoline) [Product label].
- IQVIA. (2023). Prescription Data for IBS treatments.
- EvaluatePharma. (2022). Market forecasts for GI drugs.
- Centers for Disease Control and Prevention. (2022). Prevalence estimates for IBS.
- Pharmaceutical Market Analysis. (2023). Patent expiration calendars and generic entry forecasts.
